Nucleic Acid Sentinel Lymph Node Labeling for Archival Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying sentinel lymph nodes in cancer diagnosis, such as using dyes and radiocolloids, are limited in accuracy and durability, particularly when it comes to paraffin-embedded tissues, and do not provide a reliable long-term label for subsequent analysis.
Innovation Solution
A method involving the administration of a marker nucleic acid segment, which can be a prokaryotic or eukaryotic nucleic acid, to identify sentinel lymph nodes, allowing for their detection in lymph nodes through nucleic acid hybridization and amplification techniques, even in paraffin-embedded samples, and potentially combined with dyes or radioactive isotopes for enhanced visibility.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dyes and radiocolloids are used for sentinel lymph node identification, then the nodes can be detected intraoperatively, but the labels are not durable and cannot be used for long-term analysis of paraffin-embedded tissues
Solution Approach 1:
The patent changes the fundamental parameter of the label from transient substances (dyes, radiocolloids) to stable nucleic acid markers that can be detected in paraffin-embedded tissues. This parameter change enables long-term archival and subsequent analysis, resolving the contradiction between intraoperative detectability and long-term durability.
Solution Approach 2:
The patent introduces nucleic acid markers as an intermediary substance that bridges the gap between intraoperative identification needs and long-term archival requirements. These markers serve dual purposes: enabling intraoperative detection when combined with imaging agents and providing durable labels for future molecular analysis of paraffin-embedded tissues.
2Measurement precision
If multiple lymph nodes stain blue or show radioactivity, then more nodes can be identified, but the ability to accurately categorize draining lymph node hierarchy is limited
Solution Approach 1:
The patent applies local quality by using different nucleic acid markers for different lymph node levels (sentinel vs. non-sentinel). This allows precise local identification and categorization of lymph node hierarchy, resolving the ambiguity that occurs when multiple nodes stain with the same dye or show radioactivity.
Solution Approach 2:
The patent segments the identification system by using distinct nucleic acid markers for different lymph node categories. This segmentation enables accurate differentiation between sentinel and non-sentinel nodes, providing clear hierarchical categorization without the confusion of uniform staining patterns.
3Measurement precision
If conventional staining methods are used, then the process is simple, but the detection of occult metastatic tumor cells is less sensitive
Solution Approach 1:
The patent replaces conventional mechanical staining methods with molecular detection techniques (nucleic acid hybridization, PCR). This substitution dramatically increases detection sensitivity for occult metastatic cells, allowing detection at the molecular level rather than relying on visual staining patterns.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a durable and accurate method for labeling sentinel lymph nodes, enabling precise identification and analysis, even in archived tissues, and allows for therapeutic interventions targeting these nodes.
Implementation Method 1
determining the presence or absence of the marker nucleic acid segment in a lymph node, wherein the presence of said marker nucleic acid segment in the lymph node identifies the lymph node as a sentinel lymph node
Implementation Method 2
detection in lymph nodes through nucleic acid hybridization and amplification techniques
Data Source
AI summary
The present invention describes a method for identification and labeling of sentinel lymph nodes (SLNs) and the presence or absence of lymph node metastases as an important diagnostic and prognostic factor in early stage cancers of all types. The method, know as Molecular Lymphatic Mapping, uses traditional dye/radioactive tracer based techniques in conjunction with a nucleic acid marker to identify and label the SLN, not only for current diagnostic methods, but for archival purposes. In addition, MLM can be used to deliver a therapeutic gene or genes to the SLN to activate tumor immunity to tumor cells, and/or to inhibit tumor metastases. The methods may be combined with therapeutic intervention including chemotherapy and radiotherapy.